I'm still wondering why the big 5 have not participated in the coverage of Celldex. Certainly Credit Suisse blew it BIGTIME earlier this year when they had Celldex present at their healthcare conference and fumbled the ball - not even announcing any coverage at all (not even an overwieght). If you go back and listen to the conference call, the biotech analyst was asleep at the wheel and completrely missed the value proposition that we know now is up 300% from then. Don't be surprized to see Goldman Sacs be the first of the other big 5 jump this train soon and this is where the big retail money is hiding. They should be getting their retail clients into Celldex as small cap biotech growth stock to give them some outsized gains for 2014 and beyond now as Celldex emerges as an independent commercial biotech. Private equuity firm like Blackrock could take this company private and emerge in 10 years with a juggernaut fully operational drug company worth $60-80BB. The science is stae-of-the-art, management is first-rate and the drugs are targeted immunotherapies with companion diagnostics that work to treat difficult to manage disease with high unmet medical needs with orphan drug status. What's not to like here ? ? ?